Price
No data yet.
Social Signal Score
Analyst Ratings
Revenue
$148.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mathai Mammen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 145
- Beta
- 5.03
- Country
- US
Financials
PBLS has only 4 quarterly periods on file — the charts below show the full history available.
Revenue
$148.0K+0.0%Net Income
$-52.46MEBITDA
$-51.66MFree Cash Flow
$-4.24MEPS (diluted)
$-2.32Shares Outstanding (diluted)
28.91M+1332.8%Operating Expenses
$51.03MCash & Debt
$1.12BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-145.89M | $-92.40 |
| 2024 | $0.00 | $-117.91M | $-83.48 |
Valuation
PBLShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (5)
- News (RSS)seekingalpha·19d ago·Positive
Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (RSS)investing·41d ago·Neutral
Parabilis Medicines adds former J&J oncology executive to board
View source ↗ - Newsglobenewswire.com·42d ago·Negative
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D. CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced the appointment of Craig L.
View source ↗ - Newsseekingalpha.com·52d ago·Negative
Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform Parabilis Medicines (PBLS) leverages rare, genetically simple tumors to validate its Helicon platform, aiming for broader oncology applications. PBLS holds $1.1 billion in cash, providing a runway into 2030 to support clinical trials, platform expansion, and reduce financing risk. Early zolucatetide data in desmoid tumors show 100% tumor reduction and 74% objective response, with a favorable safety profile versus com…
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors
View source ↗
Earnings
Typical surprise -1306.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-2.32 vs $-0.17miss
Estimates and results for PBLS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PBLS officers and directors.
- Bought
- $441.4m
- Sold
- —
14 trades
0 trades
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
- Sebulsky Alanbought
- Sebulsky Alanbought
68 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PBLS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.